KPIs & Operating Metrics(New)

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NovoCure (NVCR) Gains from Sales and Divestitures (2018 - 2019)

NovoCure's Gains from Sales and Divestitures history spans 2 years, with the latest figure at $723554.0 for Q2 2019.

On a quarterly basis, Gains from Sales and Divestitures rose 31.46% to $723554.0 in Q2 2019 year-over-year; TTM through Jun 2019 was $723554.0, a 31.46% increase, with the full-year FY2018 number at $556563.0, changed N/A from a year prior.
Gains from Sales and Divestitures hit $723554.0 in Q2 2019 for NovoCure, up from $391191.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for NVCR hit a ceiling of $723554.0 in Q2 2019 and a floor of $256578.0 in Q1 2018.